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Abstract
Aims/hypothesis A genome-wide association study in the
Japanese population reported two genome-wide significant
loci associated with type 2 diabetes of which the VPS13C/
C2CD4A/C2CD4B locus was replicated in Europeans. We
looked for potential associations between the diabetogenic
VPS13C/C2CD4A/C2CD4B rs7172432 variant and diabetes-
related intermediary traits.
Methods We genotyped the rs7172432 variant in the
population-based Inter99 cohort (n=6,784) and analysed
quantitative diabetes-related traits in 5,722 non-diabetic
participants who all were examined by an OGTT.
Results The diabetes-associated A allele was associated
with 0.60 cm higher waist circumference (p=0.004),
0.037 mmol/l higher fasting plasma glucose (p=4×10−5)
and 0.11 mmol/l higher plasma glucose at 30 min during an
OGTT (p=4×10−4). In analyses adjusted for concomitant
insulin sensitivity levels the diabetogenic allele was associated
with a lower acute glucose-stimulated insulin response (GSIR)
as estimated by 30 min serum insulin (β=−0.039, p=2×10−7),
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insulinogenic index (β=−0.057, p=1×10−8) and BIGTT-acute
insulin release (β=−0.041, p=9×10−9). As rs7172432 is
situated in a region previously associated with glycaemic
traits, we tested linkage disequilibrium (LD) with the reported
regional lead single-nucleotide polymorphisms for fasting
(rs11071657) and 2 h plasma glucose (rs17271305), and
performed conditional analyses of rs7172432. Rs7172432
showed moderate LD with rs11071657 and rs17271305 (R2<
0.34) and we found strong association by almost unchanged
effect sizes of rs7172432 with plasma glucose and estimates
of GSIR in analyses conditional on rs11071657 and
rs17271305.
Conclusions/interpretation The diabetogenic VPS13C/
C2CD4A/C2CD4B rs7172432 A allele associates with
GSIR in non-diabetic individuals from the general popula-
tion, suggesting an impaired beta cell function as an
intermediary diabetes-related trait.
Keywords Genetic epidemiology . Genetics .
Insulin response . Type 2 diabetes
Abbreviations
AIR Acute insulin response
GSIR Glucose-stimulated insulin response
GWAS Genome-wide association study
IR Insulin resistance
LD Linkage disequilibrium
SI Sensitivity index
SNP Single-nucleotide polymorphism
Introduction
Since 2007 the number of common validated type 2
diabetes genes has increased considerably, owing to the
results of genome-wide association studies (GWAS).
Mostly these studies have been performed in European
populations, and although many of the identified gene
variants have subsequently been replicated in other ethnic-
ities, the overlap of type 2 diabetes genes in various
ethnicities is undetermined. In 2008 the results of two
GWAS were published, highlighting KCNQ1 as a strong
type 2 diabetes susceptibility gene in the Japanese
population [1, 2]; however these studies were of limited
size with regard to both sample size and number of single-
nucleotide polymorphisms (SNPs) genotyped. Recently, a
three-stage GWAS of 459,359 SNPs in the Japanese
population was reported, showing novel genome-wide
significant associations of variants in two loci in combined
analyses of up to ∼27,000 Japanese samples [3]. Associa-
tion with type 2 diabetes was subsequently extended to
European populations of up to 15,000 Danish and French
samples for the VPS13C/C2CD4A/C2CD4B locus, showing
comparable type 2 diabetes risk increments of 10%–13% in
both East Asian and European populations [3].
The genomic region enclosing VPS13C/C2CD4A/
C2CD4B has previously been reported to influence fasting
plasma glucose (lead SNP rs11071657) [4] and plasma
glucose 2 h after an oral glucose load (lead SNP
rs17271305) [5]; yet the involved lead SNPs are in low or
moderate linkage disequilibrium (LD). We previously
reported a diminished insulin release in carriers of the
rs11071657 glucose-raising allele [6]; however, this was
not found in a meta-analysis of more than 15,000
individuals with OGTT data [7]. The rs17271305 variant
has not shown any association with insulin release [5, 7].
The objective of the current study was to determine the
intermediary mechanism responsible for risk of type 2
diabetes for the VPS13C/C2CD4A/C2CD4B lead
rs7172432 SNP by testing association with type 2
diabetes-related phenotypes in 5,722 non-diabetic individ-
uals of the population-based Inter99 cohort.
Methods
Participants The Inter99 cohort is a randomised, non-
pharmacological intervention study for the prevention of
ischaemic heart disease, conducted on 6,784 randomly
ascertained participants aged 30 to 60 years at the Research
Centre for Prevention and Health in Glostrup, Copenhagen
(ClinicalTrials.gov NCT00289237) [8]. An OGTT was
performed with measurement of plasma glucose and serum
insulin at fasting, and 30 and 120 min after glucose intake.
Subsequently, 6,094 participants of Danish nationality and
with available DNA were classified as having normal
glucose tolerance (n=4,525), impaired fasting glycaemia
(n=504), impaired glucose tolerance (n=693), screen-
detected type 2 diabetes (n=253) or previously diagnosed
diabetes (n=119) according to WHO 1999 criteria. The
analysis of quantitative diabetes-related phenotypes was
performed in 5,722 non-diabetic participants. Detailed
characteristics of Inter99 have been published previously [6].
Written informed consent was obtained from all individ-
uals before participation. The study was approved by the
Ethical Committee of Copenhagen County and conducted
in accordance with the principles of the Helsinki Declara-
tion II. Biochemical and anthropometric measures were
obtained as previously detailed [6].
Derived estimates of insulin response and insulin sensitivity
Acute insulin response (AIR) was reported as the insulino-
genic index calculated as [serum insulin (pmol/l)30min −
serum insulin (pmol/l)0min]/plasma glucose (mmol/l)30min,
and as BIGTT-AIR. Insulin sensitivity was estimated by the
HOMA of insulin resistance (IR) calculated as serum insulin
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(pmol/l)0min×plasma glucose (mmol/l)0min/135, sensitivity
index (SI) Matsuda [9] and BIGTT-SI. The BIGTT indices,
which apply information on sex and BMI, combined with
plasma glucose and serum insulin during an OGTT, to
provide indices for AIR and SI, were calculated as described
by Hansen et al. [10].
Genotyping The rs7172432 variant was genotyped by the
KASPar SNP Genotyping system (KBioscience, Hoddesdon,
UK). The success rate was 96.6 with a mismatch rate of 0.3
in 596 pairs genotyped in duplicate. The distribution of
genotypes was in Hardy–Weinberg equilibrium in Inter99
(p=0.9).
Statistical analysis General linear statistical methodology
was used to test quantitative traits in relation to genotype,
applying additive models. Values of serum insulin and
derived indices (except BIGTT-SI) were logarithmically
transformed before analysis. A p value of less than 0.05
was considered statistically significant. The exact models
are described in the results and tables. All analyses were
performed using RGui, version 2.10.0 (www.r-project.org).
Estimates of statistical power in the Inter99 cohort have
previously been reported [6].
Results
First we analysed the diabetes-associated rs7172432 in relation
to metabolic intermediary traits in Inter99 (Table 1). In a model
adjusted for age and sex the diabetes-associated A allele
associated with a per-allele 0.60 cm higher waist circumfer-
ence (p=0.004), a per-allele 0.037 mmol/l higher fasting
plasma glucose (p=4×10−5) and 0.11 mmol/l higher plasma
glucose 30 min after an oral glucose load (p=4×10−4). The
diabetogenic allele was also associated with a lower acute
glucose-stimulated insulin response (GSIR), as estimated by
30 min serum insulin (β=−0.032, p=0.003), insulinogenic
index (β=−0.052, p=1×10−5) and BIGTT-AIR (β=−0.038,
p=5×10−6). To obtain association estimates with GSIR
independent of adiposity, we adjusted analyses for BMI and
found similar association with plasma glucose levels, whereas
the association with GSIR was substantiated (Table 1). Similar
results were obtained when adjusting for waist circumference
Table 1 Quantitative metabolic traits in non-diabetic participants of the Inter99 cohort stratified according to the VPS13C/C2CD4A/C2CD4B
rs7172432 genotype
Variable GG GA AA Model 1 Model 2
N (men/women) 1,062 (516/546) 2,712 (1,313/1,399) 1,718 (859/859)
Age (years) 46±8 46±8 46±8
Adiposity measures
BMI (kg/m2) 25.7±4.3 26.1±4.4 26.1±4.4 0.17 (0.083), 0.05
Waist (cm) 85.0±12.7 85.9±12.8 86.4±13.1 0.60 (0.21), 0.004 0.23 (0.10), 0.02
Oral glucose tolerance test
Fasting plasma
glucose (mmol/l)
5.4±0.5 5.5±0.5 5.5±0.5 0.037 (0.009), 4×10−5 0.032 (0.0087), 2×10−4
30 min plasma
glucose (mmol/l)
8.4±1.7 8.6±1.7 8.6±1.7 0.11 (0.031), 4×10−4 0.096 (0.030), 0.001
120 min plasma
glucose (mmol/l)
6.0±1.6 6.0±1.5 5.9±1.5 –0.025 (0.029), 0.4 −0.040 (0.028), 0.2
Fasting serum
insulin (pmol/l)
33 (24–49) 34 (24–50) 34 (24–50) 0.0075 (0.011), 0.5 −0.0012 (0.0098), 0.9
30 min serum
insulin (pmol/l)
254 (179–364) 250 (182–354) 237 (172–348) −0.032 (0.011), 0.003 −0.040 (0.0099), 5×10−5
120 min serum
insulin (pmol/l)
140 (91–224) 155 (97–248) 159 (97–256) 0.048 (0.015), 0.002 0.037 (0.014), 0.009
Insulinogenic index 26.1 (18.0–39.1) 25.3 (17.5–37.4) 23.5 (16.4–35.1) −0.052 (0.012), 1×10−5 −0.057 (0.011), 4×10−7
BIGTT-AIR 1,700 (1,360–2,200) 1,650 (1,300–2,080) 1,570 (1,260–2,020) –0.038 (0.0082), 5×10−6
HOMA-IR 1.30 (0.93–2.0) 1.37 (0.942–2.1) 1.39 (0.937–2.09) 0.014 (0.012), 0.2 0.0048 (0.010), 0.6
BIGTT-SI 10.0±4.0 9.0±4.0 9.0±4.0 –0.13 (0.08), 0.1
SI Matsuda 8.05 (5.57–11.2) 7.78 (5.29–11) 7.76 (5.27–11.3) −0.011 (0.011), 0.3 –0.0018 (0.0096), 0.9
For each genotype data are mean±SD or median (interquartile range)
For models 1 and 2 data are estimate (SE) and p value
Estimates, SE and p values are based on additive models for the diabetes-associated major A allele
Model 1: adjusted for age and sex. Model 2: adjusted for age, sex and BMI. BIGTT-AIR and BIGTT-SI are only adjusted for age because sex and
BMI are included in the calculation of the indices
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instead of BMI (data not shown). As the individual insulin
response is highly dependent on individual concomitant levels
of insulin sensitivity, we made adjustments in the analysis of
GSIR for insulin sensitivity estimated by Matsuda’s index and
found strong effects of rs7172432 on GSIR (30 min serum
insulin: β=−0.039, p=2×10−7; insulinogenic index: β=
−0.057, p=1×10−8; BIGTT-AIR: β=−0.041, p=9×10−9).
The VPS13C/C2CD4A/C2CD4B rs7172432 variant is
positioned in a region previously associated with glycaemic
traits and we therefore tested LD with the reported lead
SNPs for genome-wide significant associations with fasting
plasma glucose (rs11071657) and plasma glucose at 2 h
during OGTT (rs17271305). Rs7172432 showed moderate
LD with rs11071657 (R2=0.27, D′=0.49) and rs17271305
(R2=0.34, D′=0.63) in the population-based Inter99 sample.
To evaluate the relationship between these variants and the
association with glucose-related traits, we performed condi-
tional analysis of the three lead SNPs. The rs7172432 variant
showed strong association by virtually unchanged effect sizes
with fasting plasma glucose and estimates of GSIR in analysis
conditional on rs11071657 (Table 2) and rs17271305
(Table 3). By contrast, in analysis conditional on rs7172432
associations of rs11071657 with fasting glucose and GSIR,
traits were strongly attenuated and non-significant (Table 2).
The same was the case for the association of rs17271305
with GSIR conditional on rs7172432; however, the associ-
ation with 2 h plasma glucose remained borderline significant
after adjustment for rs7172432 (Table 3).
Discussion
To date most of the large-scale GWAS of type 2 diabetes
and traits related to glucose homeostasis have been
Table 2 Conditional analysis of VPS13C/C2CD4A/C2CD4B rs7172432 and rs11071657 on diabetes-related intermediary traits in 5,722 non-
diabetic participants of the population-based Inter99 cohort
Explanatory variables Age, sex, log(SI Matsuda),
rs7172432a
Age, sex, log(SI Matsuda),
rs11071657a
Age, sex, log(SI Matsuda),
rs7172432a, rs11071657
Age, sex, log(SI Matsuda),
rs7172432, rs11071657a
Fasting plasma glucose (mmol/l) 0.030 (0.0084), 3×10−4 0.029 (0.0086), 8×10−4 0.021 (0.010), 0.04 0.017 (0.010), 0.1
30 min plasma glucose (mmol/l) 0.093 (0.029), 0.001 0.073 (0.03), 0.01 0.078 (0.035), 0.02 0.027 (0.035), 0.4
120 min plasma glucose (mmol/l) −0.047 (0.027), 0.08 −0.0048 (0.027), 0.9 −0.061 (0.032), 0.06 0.025 (0.032), 0.4
Fasting serum insulin (pmol/l) −0.0022 (0.0047), 0.6 −0.0087 (0.0048), 0.07 0.0019 (0.0056), 0.7 −0.0082 (0.0057), 0.1
30 min serum insulin (pmol/l) −0.039 (0.0074), 2×10−7 −0.017 (0.0076), 0.03 −0.04 (0.0088), 6×10−6 0.0029 (0.0090), 0.7
120 min serum insulin (pmol/l) 0.038 (0.01), 2×10−4 0.024 (0.01), 0.02 0.035 (0.012), 0.003 0.0054 (0.012), 0.7
Insulinogenic index −0.057 (0.01), 1×10−8 −0.029 (0.01), 0.004 −0.056 (0.012), 2×10−6 −0.00085 (0.012), 0.9
BIGTT-AIR −0.041 (0.0071), 9×10−9 −0.030 (0.0073), 4×10−5 −0.033 (0.0084), 8×10−5 −0.013 (0.0086), 0.1
Data are per-allele estimate (SE), p value for diabetes-associated major rs7172432 A allele or glucose-raising rs11071657 A allele
All analyses were performed assuming an additive model. All traits except values of plasma glucose were logarithmically transformed before
analysis. Initial findings in Inter99 on rs11071657 have been previously published [6]. Minutes are given following an OGTT
a The parameter for which the coefficient is given
Table 3 Conditional analysis of VPS13C/C2CD4A/C2CD4B rs7172432 and rs17271305 on diabetes-related intermediary traits in 5,722 non-
diabetic participants of the population-based Inter99 cohort
Explanatory variables Age, sex, log(SI Matsuda),
rs7172432a
Age, sex, log(SI Matsuda),
rs17271305a
Age, sex, log(SI Matsuda),
rs7172432a, rs17271305
Age, sex, log(SI Matsuda),
rs7172432, rs17271305a
Fasting plasma glucose (mmol/l) 0.03 (0.0084), 3×10−4 −0.014 (0.0084), 0.08 0.032 (0.01), 0.003 0.0038 (0.01), 0.7
30 min plasma glucose (mmol/l) 0.093 (0.029), 0.001 −0.064 (0.029), 0.03 0.088 (0.036), 0.01 −0.0064 (0.036), 0.9
120 min plasma glucose (mmol/l) −0.047 (0.027), 0.08 0.06 (0.027), 0.02 −0.0023 (0.033), 0.9 0.07 (0.033), 0.04
Fasting serum insulin (pmol/l) −0.0022 (0.0047), 0.6 0.0018 (0.0047), 0.7 −0.0036 (0.0058), 0.5 −0.0015 (0.0059), 0.8
30 min serum insulin (pmol/l) −0.039 (0.0074), 2×10−7 0.014 (0.0074), 0.05 −0.046 (0.0091), 6×10−7 −0.012 (0.0092), 0.2
120 min serum insulin (pmol/l) 0.038 (0.01), 2×10−4 –0.018 (0.01), 0.07 0.047 (0.012), 1×10−4 0.011 (0.012), 0.4
Insulinogenic index −0.057 (0.01), 1×10−8 0.027 (0.01), 0.008 −0.063 (0.012), 4×10−7 −0.0099 (0.012), 0.4
BIGTT-AIR −0.041 (0.0071), 9×10−9 0.02 (0.0071), 0.006 −0.044 (0.0088), 7×10−7 −0.0068 (0.0088), 0.4
Data are per-allele estimate (SE), p value for diabetes-associated major rs7172432 A allele or 2 h glucose-raising rs17271305 G allele
All analyses were performed assuming an additive model. All traits except values of plasma glucose were logarithmically transformed before
analysis. Initial findings in Inter99 on rs17271305 have been previously published [5]. Minutes are given following an OGTT
a The parameter for which the coefficient is given
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performed in populations of European ancestry. However,
recently a three-stage GWAS in Japanese individuals was
reported [3]. The lead SNP in one of two novel Japanese
type 2 diabetes susceptibility loci was also associated with
type 2 diabetes in Europeans. Here we report a strong
association with lower GSIR in risk allele carriers,
indicating an impaired beta cell function as the intermediary
phenotype increasing the risk of type 2 diabetes. The
impact of rs7172432 on GSIR was evident from analysis of
OGTT-derived estimates of stimulated insulin responses
and was substantiated by adjusting for concomitant indi-
vidual levels of insulin sensitivity. We observed a per-allele
3%–8% lower GSIR for the rs7172432 diabetes-risk allele,
which in the Danish population is comparable to the effect
sizes of the type 2 diabetes risk variants with the highest
influence on GSIR such as HHEX rs1111875 and MTNR1B
rs10830963 [11, 12]. We also show a 0.60 cm increased
waist circumference in carriers of the diabetogenic allele,
and from the current data we cannot exclude the possibility
that rs7172432 has impacts on both central obesity and the
pancreatic beta cell that together contribute to the increased
risk of type 2 diabetes. This locus has not been found in
recent large GWAS of measures of obesity, and obviously
we cannot exclude a false positive finding. We have
investigated only one SNP, but we analysed 13 traits, and
although these traits are correlated, the association with
waist circumference is merely borderline significant at a
Bonferroni-corrected significance threshold of 0.004. This
is in contrast to p values of association with estimates of
insulin release that are well below the Bonferroni-corrected
significance threshold.
The genomic region in which rs7172432 is located has
recently been shown to contain SNPs increasing fasting
plasma glucose and plasma glucose 2 h after an oral
glucose load in a non-diabetic population compiled by the
Meta-Analysis of Glucose and Insulin-related Trait Con-
sortium (MAGIC) [4, 5]. The rs17271305 variant associat-
ed with glucose at 2 h is situated in the neighbouring
VPS13C gene, whereas the fasting glucose lead SNP
(rs11071657) is located between the C2CD4A and
C2CD4B genes. In conditional analyses we show that in
5,722 non-diabetic individuals of the Inter99 sample, the
rs7172432 variant has an effect superior to rs11071657 on
fasting plasma glucose and measures of GSIR; however, the
association signals from rs7172432 and rs11071657 do not
seem to be independent as analysis of rs11071657
conditional on rs7172432 attenuated this signal strongly.
Yet, whether the rs7172432 plays a functional role in
decreasing GSIR and increasing fasting glucose and risk of
type 2 diabetes is unknown. rs7172432 is located between
C2CD4A and C2CD4B and may lead to regulatory changes
in gene expression or be in LD with an as-yet-undefined
functional variant. Very little is known about the biological
function of VPS13C, C2CD4A and C2CD4B, and the
molecular relation to glucose homeostasis and beta cell
function is unknown. Of interest, all three genes are
expressed in the pancreas and in the beta cells [4, 5] and
may therefore regulate insulin release or beta cell function.
Further large-scale studies fine-mapping this region com-
bined with functional studies may elucidate these matters.
Yet this case highlights the value of performing genetic
studies in the form of GWAS or fine-mapping efforts in
various ethnic populations to locate functional elements in
disease associations. In the near future this aspect will
probably be very valuable with the emergence of novel
second-generation dense SNP genotyping arrays. Here a
more precise relationship between association signals from
various ethnic populations can be achieved to narrow the
region containing the causal variant.
In conclusion, we demonstrate that the recently described
diabetogenicVPS13C/C2CD4A/C2CD4B rs7172432 A allele
associates strongly with glucose-stimulated insulin release in
non-diabetic individuals from the general Danish population,
suggesting an impaired beta cell function as the intermediary
diabetes-causing mechanism.
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